GRAL stock crashed after the NHS-Galleri trial failed to meet its primary endpoint. Here is what still looked positive, and whether you should buy the dip.
MRNA stock declined in after-hours trading following the FDA's refusal-to-file letter regarding its mRNA flu vaccine application. Here are the full details, and the key price levels traders are watching.
Atlassian stock ($TEAM) trades near 2018 prices despite revenue growing ~6x. See what’s driving the rerating, key risks, and what could revalue the stock.
APP stock jumped ahead of earnings after a key retracement eased headline risk and prompted shorts to cover. Here are the drivers, risks, and key levels to watch.